5434-26-4Relevant academic research and scientific papers
Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: A new therapeutic approach for amyotrophic lateral sclerosis
Rojas-Prats, Elisa,Martinez-Gonzalez, Loreto,Gonzalo-Consuegra, Claudia,Liachko, Nicole F.,Perez, Concepción,Ramírez, David,Kraemer, Brian C.,Martin-Requero, ángeles,Perez, Daniel I.,Gil, Carmen,de Lago, Eva,Martinez, Ana
supporting information, (2020/11/12)
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with no known cure. Aggregates of the nuclear protein TDP-43 have been recognized as a hallmark of proteinopathy in both familial and sporadic cases of ALS. Post-translational modifications of this protein, include hyperphosphorylation, cause disruption of TDP-43 homeostasis and as a consequence, promotion of its neurotoxicity. Among the kinases involved in these changes, cell division cycle kinase 7 (CDC7) plays an important role by directly phosphorylating TDP-43. In the present manuscript the discovery, synthesis, and optimization of a new family of selective and ATP-competitive CDC7 inhibitors based on 6-mercaptopurine scaffold are described. Moreover, we demonstrate the ability of these inhibitors to reduce TDP-43 phosphorylation in both cell cultures and transgenic animal models such as C. elegans and Prp-hTDP43 (A315T) mice. Altogether, the compounds described here may be useful as versatile tools to explore the role of CDC7 in TDP-43 phosphorylation and also as new drug candidates for the future development of ALS therapies.
Inhibition of nucleoside transport by new analogues of 4- nitrobenzylthioinosine: Replacement of the ribose moiety by substituted benzyl groups
Tromp, Reynier A.,Van Ameijde, Susan,Pütz, Claudia,Sundermann, Corinna,Sundermann, Bernd,Von Frijtag Drabbe Künzel, Jacobien K.,Ijzerman, Adriaan P.
, p. 5441 - 5450 (2007/10/03)
4-Nitrobenzylthioinosine (NBTI, 1) is a well-known inhibitor for the nucleoside transport protein ENT1. However, its highly polar nature is unfavorable for oral absorption and/or penetration into the CNS. In the search for compounds with lower polarity th
New analogs of nitrobenzylthioinosine
-
Page/Page column 6; 32, (2010/11/29)
This invention relates to new analogs or derivatives of nitrobenzylthioinosine, use of these new analogs of nitrobenzylthioinosine for the treatment of pain and various other diseases as well as pharmaceuticals comprising at least on new analog of nitrobenzylthioinosine.
Inhibition of nucleoside transport by new analogues of nitrobenzylthioinosine
Deghati, Paymaneh Y. F.,Borghini, Alice,Van Den Nieuwendijk, Adrianus M. C. H.,Dissen-de Groote, Miriam,IJzerman, Adriaan P.
, p. 899 - 908 (2007/10/03)
Nitrobenzylthioinosine (NBTI, 1) was systematically modified by attachment of substituents at positions C6 and N9, and also by substitution of N1 with C. These modifications were chosen to reduce the polarity of the new compounds. Incorporation of the nitro functionality into a benzoxadiazole ring system was considered first. These new nucleosides showed high affinity (1.5-10 nM) towards the nucleoside transport protein as present on human erythrocyte ghosts. Next, modification of this benzoxadiazole ring system with C, S and O in different positions produced a number of less polar nucleosides with affinity in the higher nanomolar range. Modification of N9 was achieved with different alkyl and alcohol substituents. An n-butyl substituent proved best, although all variations yielded substantial decreases in affinity. Replacement of N1 by a carbon atom in combination with a 2-Cl substituent also resulted in a relatively potent NBTI derivative (47 nM).
